Royalty Pharma (RPRX) Long-Term Debt Repayments (2020)

Royalty Pharma (RPRX) posted Long-Term Debt Repayments of $5.9 billion for Q3 2020, up 15.0% sequentially from $5.2 billion in Q1 2020.

Royalty Pharma (RPRX) Long-Term Debt Repayments (2020) Analysis & Trends

Royalty Pharma has reported Long-Term Debt Repayments for 1 years, with the latest figure at $5.9 billion in Q3 2020.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $5.9 billion in Q3 2020, while the trailing twelve-month figure through Jun 2021 was $5.9 billion (up 15.0% YoY) and the FY2020 annual result came in at $11.1 billion, changed N/A from the prior year.
Long-Term Debt Repayments grew to $5.9 billion in Q3 2020 per RPRX's latest filing, from $5.2 billion in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $5.9 billion in Q3 2020 and troughed at $5.2 billion in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	17.05 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn	-

Download Data